[PDF][PDF] miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis

N Sonda, F Simonato, E Peranzoni, B Calì, S Bortoluzzi… - Immunity, 2013 - cell.com
N Sonda, F Simonato, E Peranzoni, B Calì, S Bortoluzzi, A Bisognin, E Wang, FM Marincola…
Immunity, 2013cell.com
Tumor progression is accompanied by an altered myelopoiesis causing the accumulation of
immunosuppressive cells. Here, we showed that miR-142-3p downregulation promoted
macrophage differentiation and determined the acquisition of their immunosuppressive
function in tumor. Tumor-released cytokines signaling through gp130, the common subunit
of the interleukin-6 cytokine receptor family, induced the LAP∗ isoform of C/EBPβ
transcription factor, promoting macrophage generation. miR-142-3p downregulated gp130 …
Summary
Tumor progression is accompanied by an altered myelopoiesis causing the accumulation of immunosuppressive cells. Here, we showed that miR-142-3p downregulation promoted macrophage differentiation and determined the acquisition of their immunosuppressive function in tumor. Tumor-released cytokines signaling through gp130, the common subunit of the interleukin-6 cytokine receptor family, induced the LAP isoform of C/EBPβ transcription factor, promoting macrophage generation. miR-142-3p downregulated gp130 by canonical binding to its messenger RNA (mRNA) 3' UTR and repressed C/EBPβ LAP by noncanonical binding to its 5' mRNA coding sequence. Enforced miR expression impaired macrophage differentiation both in vitro and in vivo. Mice constitutively expressing miR-142-3p in the bone marrow showed a marked increase in survival following immunotherapy with tumor-specific T lymphocytes. By modulating a specific miR in bone marrow precursors, we thus demonstrated the feasibility of altering tumor-induced macrophage differentiation as a potent tool to improve the efficacy of cancer immunotherapy.
cell.com